Fresenius Medical Care Deutschland GmbH, Research and Development, Bad Homburg, Germany.
Clin J Am Soc Nephrol. 2013 Sep;8(9):1575-82. doi: 10.2215/CJN.12411212. Epub 2013 Aug 15.
Achieving and maintaining optimal fluid status remains a major challenge in hemodialysis therapy. The aim of this interventional study was to assess the feasibility and clinical consequences of active fluid management guided by bioimpedance spectroscopy in chronic hemodialysis patients.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Fluid status was optimized prospectively in 55 chronic hemodialysis patients over 3 months (November 2011 to February 2012). Predialysis fluid overload was measured weekly using the Fresenius Body Composition Monitor. Time-averaged fluid overload was calculated as the average between pre- and postdialysis fluid overload. The study aimed to bring the time-averaged fluid overload of all patients into a target range of 0.5 ± 0.75 L within the first month and maintain optimal fluid status until study end. Postweight was adjusted weekly according to a predefined protocol.
Time-averaged fluid overload in the complete study cohort was 0.9 ± 1.6 L at baseline and 0.6 ± 1.1 L at study end. Time-averaged fluid overload decreased by -1.20 ± 1.32 L (P<0.01) in the fluid-overloaded group (n=17), remained unchanged in the normovolemic group (n=26, P=0.59), and increased by 0.59 ± 0.76 L (P=0.02) in the dehydrated group (n=12). Every 1 L change in fluid overload was accompanied by a 9.9 mmHg/L change in predialysis systolic BP (r=0.55, P<0.001). At study end, 76% of all patients were either on time-averaged fluid overload target or at least closer to target than at study start. The number of intradialytic symptoms did not change significantly in any of the subgroups.
Active fluid management guided by bioimpedance spectroscopy was associated with an improvement in overall fluid status and BP.
在血液透析治疗中,实现并维持最佳的液体状态仍然是一个主要挑战。本干预研究的目的是评估生物阻抗谱指导下的主动液体管理在慢性血液透析患者中的可行性和临床结果。
设计、地点、参与者和测量方法:55 例慢性血液透析患者前瞻性优化液体状态,时间为 3 个月(2011 年 11 月至 2012 年 2 月)。每周使用 Fresenius 身体成分监测仪测量预透析时的液体超负荷。时间平均液体超负荷被计算为预透析和后透析液体超负荷之间的平均值。研究旨在在第一个月内将所有患者的时间平均液体超负荷降低至 0.5±0.75L 的目标范围,并维持最佳液体状态直至研究结束。根据预先制定的方案每周调整后体重。
在完整的研究队列中,基线时的时间平均液体超负荷为 0.9±1.6L,研究结束时为 0.6±1.1L。在液体超负荷组(n=17)中,时间平均液体超负荷降低了-1.20±1.32L(P<0.01),在正常血容量组(n=26,P=0.59)中保持不变,在脱水组(n=12)中增加了 0.59±0.76L(P=0.02)。液体超负荷每变化 1L,透析前收缩压变化 9.9mmHg/L(r=0.55,P<0.001)。研究结束时,所有患者中有 76%达到或至少比研究开始时更接近时间平均液体超负荷目标。任何亚组的透析内症状数量均无显著变化。
生物阻抗谱指导下的主动液体管理与整体液体状态和血压的改善相关。